A history of a heart attack-Yes, once Posts on Medivizor
Navigation Menu

A history of a heart attack-Yes, once Posts on Medivizor

Using beta blockers after a heart attack and long-term patient outcomes

Using beta blockers after a heart attack and long-term patient outcomes

Posted by on Aug 8, 2021 in Coronary artery disease | 0 comments

In a nutshell This study looked at how beta-blockers affected patients following a heart attack. It found that patients using a low dose of beta-blockers had better outcomes one year later. Some background Following a heart attack, there are several treatment options available to improve outcomes. One treatment is beta-blockers (BBs), which prevent...

Read More

Do beta-blockers and renin-angiotensin system inhibitors reduce the risk of events after coronary revascularization?

Do beta-blockers and renin-angiotensin system inhibitors reduce the risk of events after coronary revascularization?

Posted by on Oct 17, 2020 in Coronary artery disease | 0 comments

In a nutshell This study investigated if certain types of anti-hypertensive drugs (AHTs) reduce risks after revascularization procedures for a heart attack. They found that beta-blockers (BBs) and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) reduce cardiovascular events (CVEs) after revascularization. Some...

Read More

Ticagrelor vs. prasugrel – which is more effective as a maintenance treatment after a heart attack?

Posted by on Mar 19, 2020 in Coronary artery disease | 0 comments

In a nutshell This study compared ticagrelor (Brilique) and prasugrel (Efient) as a maintenance antiplatelet therapy (APT) after a myocardial infarction (MI; heart attack). They found that ticagrelor had a better APT effect and fewer bleeding events. Some background Coronary artery disease (CAD) is a condition that leads to...

Read More

Biodegradable sirolimus versus durable everolimus stents – which is more effective after a heart attack?

Posted by on Oct 12, 2019 in Coronary artery disease | 0 comments

In a nutshell This study investigated the effects of different drug-eluting stents (DES) in percutaneous coronary intervention (PCI) in patients who have had a heart attack. They found that biodegradable sirolimus (BS) stents were better than durable polymer everolimus (DPE) stents in improving blood flow.  Some background Percutaneous...

Read More

Which blood pressure lowering drug better protects the heart after a heart attack in patients with diabetes?

Posted by on Dec 22, 2018 in Coronary artery disease | 0 comments

In a nutshell The aim of this study was to compare the effectiveness of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARBs) in protecting the heart in patients with diabetes that have had a heart attack and who had stents placed. The main finding of the study was that ACEI reduced the risk of major adverse...

Read More

What are the long-term outcomes of treatments for MINOCA disease?

Posted by on Jun 5, 2017 in Coronary artery disease | 0 comments

In a nutshell This study aimed to investigate the long-term effects of different treatments for patients with myocardial infarction with non-obstructive coronary artery (MINOCA) disease. This study concluded that statins and ACE inhibitors/angiotensin receptor blockers provided long-term benefit to patients with MINOCA disease.  Some background...

Read More

Can using two inhibitors increase the risk of heart related events in diabetes patients?

Posted by on May 23, 2017 in Coronary artery disease | 0 comments

In a nutshell This study aimed to investigate if using both an angiotensin converting enzyme (ACE) inhibitor and a dipeptidyl peptidase 4 inhibitor, alogliptin (Nesina) in type 2 diabetes mellitus patients with recent acute coronary syndrome led to increased risk of cardiovascular events. This study concluded there was no increased risk of...

Read More

Can diabetic status help in determining adverse events of acute coronary syndromes?

Posted by on Apr 4, 2017 in Coronary artery disease | 0 comments

In a nutshell This study aimed to determine the timing of mortality and other non-fatal adverse events according to diabetic status and type of acute coronary syndrome (ACS). It was found that the type of ACS but not the diabetic status determines the timing of fatal and non-fatal adverse events. Some background Patients with diabetes mellitus...

Read More